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sure which dictate the homing profiles of lymphocytes they 
stimulate. In IBD, site and activity of disease are reflected in 
changes in homing/activation of gut DCs and T-cells they 
stimulate and also, in greater gut specificity and activation 
of blood DC. Homing potential of DC can be modulated to-
ward mucosa or skin by vitamins A and D, respectively. Inf-
liximab or interleukin-6 can divert homing profiles toward 
skin, perhaps predisposing to skin involvement in IBD. Pro-
biotic bacteria or their products can also change homing 
profiles of gut DC toward skin homing and away from gut. 
 Conclusions: In conclusion, development of gut focused in-
flammation and its treatment relies on changes in DC tissue 
specificity; therefore, removal or diversion of gut-homing DC 
as well as T-cells is likely to be critical in prevention of gut-
focused inflammation in IBD.   © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Dendritic cells (DCs) determine the tissue specificity 
of the lymphocytes they stimulate  [1] . Immune activity 
can, thus, be envisaged as a series of circuits of DCs and 
lymphocytes, each circuit with an established tissue ‘post-
al or zip code’ that determines their site of activity ( fig. 1 ). 
However, this neat pattern may hold in health but falls 
down in the face of disease and its treatment.
 An indication of acquired tissue specificity of human 
DC was first determined in early work on reactive arthri-
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 Abstract 
 Background: Dendritic, antigen-presenting cells (DCs) de-
termine not only whether lymphocytes produce different 
types of immune response but also tissue-homing profiles of 
lymphocytes they stimulate. For example, in health, mucosal 
DC stimulate T cells focused to home to the mucosa; DC/T-
cell circuitry thus targets immune responses to specific tis-
sue locations. Therapies being introduced for inflammatory 
bowel disease (IBD) include antibodies to gut-homing mol-
ecules such as α4β7 (Vedolizumab) used ostensibly to block 
gut-homing lymphocytes. However, such lymphocytes are 
dependent on the tissue specificity of DC that stimulated 
them.  Key Messages: In health, blood DCs have the potential 
to home to multiple tissues including gut (α4β7+) and skin 
(CLA+). DCs have become gut-specific within the intestinal 
microenvironment stimulated partially by local retinoid to 
express α4β7 (mucosal homing marker) and/or CCR9 (ileal 
homing marker) in the absence of skin-specific indicators. 
They spread veiled extensions, sample their environment, 
acquire/process antigens, produce cytokines and initiate in-
nate immunity. Myeloid DC also traffic to draining lymph 
nodes where compartmentalization of adaptive immune re-
sponses is determined by DCs from the site of antigen expo-
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tis following genital tract infection with  Chlamydia tra-
chomatis . Elementary bodies of  C. trachomatis bind to 
collagen, an association believed to underlie the develop-
ment of arthritis occurring in the collagen rich environ-
ment of the joint. There was a prevailing view that cross-
reactive stimulation of immunity to collagen occurred 
because of its association with chlamydia and caused ac-
cumulation and/or stimulation of collagen-specific T-
cells within the joint. However, DCs in the joints, but not 
systemically, carried the chlamydial antigens in post-
chlamydial arthritis. By contrast, T-cells present in the 
joint merely reflected the systemic increase in chlamydia-
specific T-cells that followed the genital tract infection 
 [2] . In exact contradiction to the prevailing view, my in-
terpretation was that there was non-responsiveness to a 
self-associated antigen on DC in the joint; there are prec-
edents for non-responsiveness to foreign antigens linked 
to self-antigens  [3, 4] . This non-responsiveness meant 
that DCs bearing the chlamydial antigen persisted, con-
tinued to produce innate immune effects locally in the 
joint but did not migrate from the joint to lymph nodes 
to stimulate a local adaptive immune response. Together 
with the lack of activity of the circulating, chlamydia-spe-
cific T-cells to remove chlamydial antigen from the joint, 
these unexpected findings indicated the presence of a lo-
calized immune focus of non-responsiveness involving 
both DCs and T-cells. The observations spawned the con-
cept of local circuits of immune responses involving both 
DCs and T-cells. The formal demonstration of such cir-
cuitry  [1] has been followed by my aim of developing ef-
fective, tissue-specific, DC/lymphocyte circuits of re-
sponsiveness or of non-responsiveness/tolerance to ma-
nipulate responses to particular antigens for effective 
control of immunity. A circuit of non-responsiveness 
would preserve the integrity of a tissue expressing self-
antigens or self-associated antigens whilst a responsive 
circuit would not only remove unwanted foreign antigen-
ic incursions but also act as an immunological barrier to 
the growth of tissue at inappropriate sites (including tu-
mors –unless they carried local self-antigens). These con-
cepts are beginning to be understood and are relevant to 
the study of mucosal immunity and to understanding the 
development of IBD and its treatment.
 The knowledge of specific T-cell homing markers and 
their ligands  [5, 6] was instrumental in being able to de-
termine the involvement of DC in tissue homing of T-
cells, and this knowledge allowed formal demonstration 
of the hypothesis that DCs were involved in determining 
tissue homing  [1] . Thus, DCs from the gut or the gut-
draining lymph nodes stimulated the development of 
gut-homing lymphocytes whilst the peripheral DC stim-
ulated skin homing lymphocytes  [1, 7–9] ; the source of 
the lymphocytes did not influence the migration poten-
tial  [1] . Parallel studies showing the rapid acquisition of 
tissue-specific homing phenotypes by CD4 T-cells acti-
vated in cutaneous or mucosal lymphoid tissues support-
ed the idea of local involvement of tissue-specific ele-
ments during the T-cell activation process  [10] .
 Such concepts of responsiveness and non-responsive-
ness in different circuits of DCs and T-cells, and the in-
volvement of innate and adaptive arms of immune re-
sponse, may inform understanding of the processes un-
derlying the role of antigens within the gut such as food 
and the gut microbiota that could either promote or dis-
courage inflammation in the gut. Direct evidence of the 
critical importance of site of sensitization in relation to 
the site of inflammation induced by gut antigens in hu-
mans in IBD was obtained from early studies of sensitiv-
ity to food antigens in Crohn’s disease. In Crohn’s dis-
ease, there is increased permeability of the gut mucosa 
predisposing to the breaching of this barrier by food an-
tigens as well as by the microbiota. The induction of sys-
temic sensitivity to such antigens was, therefore, studied 
in patients and controls by examining the development of 
recall or memory T-cell responses to a selection of anti-
gens that are met in the gut. Antigens studied were ex-
tracts of cow’s milk, cereals, cabbage group, citrus fruits, 
peanut group, yeast and bacteria. In Crohn’s disease but 
not controls, the reactivity of peripheral lymphocytes to 
these antigenic extracts, particularly multiple sensitivi-
ties, was common  [11] ( fig. 1 b). Despite this evidence of 
systemic sensitization, inflammation in response to skin 
challenge was negative; however, inflammation on intra-
rectal challenge with these antigens, often to multiple an-
tigens, was again common in the Crohn’s patients but not 
in controls  [12] . The relationship between the site of sen-
sitization and site of recall/inflammation was established 
indicating the relevance of compartmentalization of im-
mune responses in gut inflammation in response to intes-
tinal antigens in Crohn’s disease. Thus, identification of 
sensitivity to particular gut antigens in IBD requires test-
ing at the mucosal site or via gut-specific elements sys-
temically.
 Homing Marker Expression on DC 
 The finding that the tissue source of the DC deter-
mined the migration pathways of lymphocytes they stim-
ulate indicated that the DC themselves must have tissue 
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specificity. The majority of blood T-cells, in health, ex-
press α4β7 in the absence of skin homing markers indi-
cating that they have been ‘educated’ in the mucosa and 
have the capacity to home to the ligand mucosal vascular 
addressin cell-adhesion molecule 1 expressed by post-
capillary endothelial cells in intestinal lamina propria. A 
smaller percentage of T-cells express skin homing mark-
ers without gut-homing potential. By contrast, around 
80% of blood DCs in health have both gut and skin hom-
ing potential as indicated from expression of both α4β7 
and CLA, respectively  [13] . Since the major evidence 
from animal models is that DC do not recirculate but die 
in the lymph nodes  [14, 15] , the multi-homing potential 
of blood DC is likely to be necessary to facilitate the dis-
tribution to different tissues of DC emerging from the 
bone marrow into blood. Once within the tissues, DC ex-
posed to antigens locally will continue a pattern of matu-
ration of chemokine receptors that helped to localize 
them to these different tissues and upregulate the chemo-
kine receptor CCR7 (giving responsiveness to CCL19/21) 
which promotes homing via the afferent lymph to the 
lymph nodes  [16] . Here, they can stimulate tissue-specif-
ic responses in naive lymphocytes that also locate there by 
virtue of their CCR7 expression.
 Once the DCs reach the skin or gut, local environmen-
tal factors promote their tissue specificity; gut DC remain 
largely α4β7 positive but lose skin homing receptor for 
E-selection, CLA, although some colonic but not ileal DC 
 Fig. 1. DC/T-cell circuitry.  a In the resting 
state, most DCs within a tissue are tissue 
specific as illustrated from the expression 
of gut-specific α4β7 in gut mucosa or CLA 
in the skin. DCs will be exposed only to lo-
cal tissue antigens and the migration of tis-
sue-specific DCs to draining lymph nodes 
is minimal. Consequently, low numbers of 
lymphocytes are clustered and activated in 
the lymph node and there is little develop-
ment of tissue-specific lymphocytes or of 
their release into the circulation.  b Expo-
sure of tissue to foreign antigen (Ag) in the 
gut is illustrated. Antigen is passed between 
DC and recognition of difference or poten-
tially damaging effects promotes activation 
and migration of DC to draining lymph 
node. Antigen-specific gut DC within the 
draining lymph node will cluster and acti-
vate Ag-specific, gut-homing lymphocytes 
that are released into the circulation. These 
cells will home back to the gut toward the 
ligand for α4β7, mucosal vascular ad-
dressin cell-adhesion molecule 1, expressed 
by post-capillary endothelial cells in intes-
tinal lamina propria. Specific targeted im-
munity to the foreign antigen in the gut will 
result. These cells will not have homing po-
tential to other tissues such as the skin. Dis-
ease states, exposure to some bacteria or 
treatments for IBD can alter the activation 
and tissue-specificity of DC and subse-
quently of the lymphocytes they stimulate; 
such changes can change the activity or tis-
sue restrictions of inflammatory disease or 
the immune responses to them. 
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may maintain or acquire some skin-homing potential  [8, 
17] . Skin specificity without gut potential is found in 
many DCs in the skin  [13] . A major instigator of the gut 
specificity for DC is retinoic acid which can also inhibit 
the T-cell stimulatory function of DC  [18–20] , albeit very 
low doses of retinoid may promote T-cell stimulation 
 [18] . An effect of retinoic acid on monocyte-derived DC 
(MoDC) in vitro is to upregulate α4β7 and promote pro-
duction of TGFβ and interleukin (IL)-6  [19] . However, 
MoDC differ from normal circulating blood DC in their 
tissue specificities. The blood monocytes themselves 
from which MoDC are derived, unlike DC, lack expres-
sion of both CLA and α4β7 but express CCR9, an ileal 
homing marker, and CCR5 which gives the capacity to 
migrate to inflamed tissues  [20] . Following the culture 
period to obtain MoDC, the cells lack migration markers 
and could be said to be ‘homeless’; such lack of tissue di-
rection may be a fundamental problem when trying to use 
MoDC therapeutically, perhaps underlying the disap-
pointing results of attempted in vivo treatments with 
MoDC, particularly for tumors. The appropriate activa-
tion of immunity in vitro may not be realized in vivo if 
DCs are not equipped to direct immune responses to the 
required location. However, stable induction of α4β7 
could be promoted in MoDC to provide the potential for 
migration to mucosal tissue  [20] . Evidence that this pro-
cess of inducing gut specificity occurs within the human 
gut environment in health was obtained by showing that 
blood DC exposed to the supernatants of normal human 
colonic biopsies upregulate both α4β7 and CCR9 on DCs, 
an effect which is prevented by blocking retinoic acid ac-
tivity  [13] . CCR9 is also a homing receptor for plasmacy-
toid DCs travelling to the ileum as well as for the myeloid 
DCs  [21] . A proportion of myeloid DCs from the ileum, 
and to a smaller extent those from the distal but not the 
proximal colon, express CCR9 and stimulate the produc-
tion of CCR9-positive T-cells licensing them to migrate 
to CCL25/TECK expressed on ileal epithelial cells  [17, 
22] . Another migration marker involved in migration of 
both monocytes and DC to the gut is CCR2  [22] . In con-
trast to the functions of retinoic acid, vitamin D may in-
fluence leukocyte homing toward the skin.
 Changes in IBD 
 There is increasing information describing the subsets 
and properties of human intestinal DC  [17, 22–25] . Dif-
ferences are now being defined in health between DC in 
ileum and colon  [17] and between proximal and distal 
colon  [22] which make the interpretation of data difficult 
where these locations have not been defined. In any case, 
detailed descriptions of alterations in human intestinal 
DC in IBD and analyses of homing marker expression on 
different subsets of intestinal DC in IBD are rare  [23, 26–
29] . A predominant cytokine in the inflamed gut in ulcer-
ative colitis is IL-6 which could promote skin homing in 
DC and T-cells they stimulate, an effect also reported with 
supernatants and cells of biopsies from inflamed areas of 
the gut  [30, 31] . Such an effect could possibly fuel skin 
involvement in some patients. However, despite this ob-
servation, in other studies, where colonic DC were col-
lected as cells migrating from biopsies from ulcerative 
colitis patients, these DC induced lower expression of the 
skin homing markers CLA and CCR4 on stimulated T-
cells compared with their healthy counterparts. These gut 
DC from ulcerative colitis patients also induced enhanced 
expression of the ileal homing marker CCR9 on stimu-
lated allogeneic T-cells; expression of β7 integrin was ini-
tially high and remained so. Thus, the gut DCs in these 
ulcerative colitis patients induced a greater T-cell focus 
toward the gut and away from the skin suggesting promo-
tion of increased gut-specific activity; the activity was ac-
companied by increased IL-4 production and a loss of 
IL-22 and IFNγ  [28] . It is worth remembering, however, 
the great plasticity of DC so that single snapshots of gut 
DC activity will not provide a coherent picture and appar-
ent effects on T-cells may be offset by the presence of per-
sistent memory T-cells with a predetermined migratory 
potential.
 A surprising finding is that blood DCs can act as a win-
dow on site and activity of disease in IBD; both the DCs 
and the T-cells in the blood in IBD can reflect the site of 
the disease within the gut and its activity. The DCs give a 
clearer picture of ongoing activity since expression of 
markers on activated DCs able to stimulate T-cells is not 
confounded by the persistence of homing markers such 
as α4β7 on pre-existing, long-lived, memory T-cells. The 
site of disease and its activity can be identified from 
changes in the migration markers and activation markers 
on blood DC. Thus, increases in CCR9 on blood DC con-
comitant with loss of skin homing potential is evident in 
many adult Crohn’s patients and in a smaller proportion 
of pediatric Crohn’s patients  [32, 33] ; this blood DC 
change reflects the presence of ileal disease. There is also 
a loss in Crohn’s patients of the double skin and gut hom-
ing DC population which is replaced by cells showing 
only gut specificity with high β7 expression – that is of DC 
resembling those normally only found in quantity in the 
gut  [33] . The mechanisms producing this effective change 
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in DC life history are unknown but include the possibil-
ity of recirculation of DC that have located to the gut, 
been stimulated, travelled to the lymph node and then 
recirculated via the efferent lymph; the gut-homing phe-
notype and the presence of CCR7 that favors lymph node 
homing on blood DC makes the recirculation idea likely. 
Alternatively, changes in systemic cytokine profiles that 
affect homing activity may occur.
 In Crohn’s disease with concomitant erythema nodo-
sum, changes in the presence and acquisition of a skin 
homing profile in γδ T-cells was observed and resolved 
following successful treatment with steroids  [34] . Thus, 
different subsets of T-cells may be differentially regulated 
in diseases reflecting different sites of disease, but the 
types of DC that may be involved in their stimulation has 
not always been determined. However, it is increasingly 
apparent that changes in the expression of homing mark-
ers and the activation profiles in blood DC and the lym-
phocytes they stimulate may contribute to the diagnosis 
and determining treatment options for IBD.
 Treatment-Induced Changes in DC Homing Potential 
 In some patients, effective therapy is achieved by 
blocking gut-homing T-cells using natalizumab (anti-α4) 
and particularly using vedolizumab (anti-α4β7); the latter 
avoids the potential dangers of interfering with brain 
tropic α4β1-positive cells, a possible risk with natalizum-
ab  [35] . Such successful approaches to therapy underline 
the importance of DC/T-cell circuitry in IBD.
 However, other biological agents also alter the migra-
tion potential of DC and the lymphocytes they stimulate. 
The probiotic  Lactobacillus casei was effective in changing 
the DC stimulatory potential of T-cells by promoting a ho-
meostatic profile and making DC once again double posi-
tive for both skin and gut-homing markers; however, it 
failed to effect change in imprinting of CCR4 or of the gut-
homing indicators CCR9 or β7  [31] . An exciting develop-
ment is the discovery that some products of probiotic bac-
teria – or ‘postbiotics’ – may have therapeutic potential 
 [36] . We have identified one such bacterial peptide, STp, 
from  Lactobacillus plantarum which may have therapeutic 
value in IBD in part via its effects on homing profiles of DC 
and lymphocytes they stimulate. STp is a serine-threonine 
rich peptide which lacks cleavage sites and, therefore, re-
sists breakdown by gut proteases. STp has anti-inflamma-
tory effects on DC and reverses changes identified in gut 
DC studied ex vivo from ulcerative colitis patients. How-
ever, STp also changes the homing profiles of DC; through 
effects on the DC, STp instructs T-cells not only to reduce 
gut specificity but also increases their potential for migrat-
ing to the skin  [26, 37] . Such a diversionary tactic represents 
a novel way by which bacteria avoid detection and elimina-
tion by the adaptive immune system. T-cells stimulated by 
DC which have this changed tissue specificity will be sent 
on a wild goose chase to the skin where it is likely that they 
will not encounter the sensitizing bacteria since this site 
lacks intestinal microbiota. A by-product of diversion to 
the skin may, however, be the propensity for producing 
skin manifestations of disease where activated DCs or T-
cells sent to the skin may initiate inflammation through lo-
cal innate effects. Another treatment which diverts lym-
phocytes to the skin is Infliximab. T-cells increase their skin 
homing profile and changes may again determine the skin 
involvement that can follow infliximab treatment  [38] .
 Enteral nutrition in pediatric Crohn’s is an effective 
treatment for a high proportion of patients and, in paral-
lel with the therapeutic effects, reverses many of the de-
fects and changes in blood DC in patients with colonic 
but not ileal disease. The latter non-responsive group 
with ileal disease can be identified by high CCR9 on blood 
DC. The enteral nutrition, when successful, normalizes 
the tissue-homing profile of the blood DC so that they 
once again show little sign of activation and have both gut 
and skin homing potential commensurate with that seen 
in health.
 Conclusions 
 The evidence for DC/T-cell immune circuits is now 
overwhelming and indicates that the normal immune 
system can be neatly compartmentalized into tissue-spe-
cific cell circuits; such a circuit will provide tissue-specif-
ic response to local foreign antigens or lack of inflamma-
tory response to self-antigens and, probably, to self-asso-
ciated, antigens for that tissue. Evidence for changes in 
these circuits is increasingly found in IBD which results 
in greater focus of immune activity toward the gut. Fur-
thermore, reflections of this change of focus and activity 
can often be identified systemically as well as in the gut 
itself; indeed, the DC in the blood can provide a window 
suggesting both the location within the gut of ongoing 
immune activity and the level of activation which are in-
dicated by DC homing markers and maturation/activa-
tion status respectively. The picture may be reflected in 
the circulating memory lymphocytes but is more difficult 
to gauge due to long-term lymphocyte survival and mem-
ory of past history within lymphocyte populations. De-
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spite the growing evidence for the importance of the DC/
lymphocyte axis in the development and control of im-
mune responses, including those in the gut, therapeutic 
control of immune activity is still predicated on diverting 
or removing effector lymphocytes systemically or from 
migration to the gut. Tackling more directly the instiga-
tors of the immune localization, the DC, may provide a 
further step forward for treatment. Despite the focus and 
importance of effector T-cells, it is becoming evident that 
effectiveness of many treatments used for IBD may stem 
from changes in the DC which reduce the focus of im-
mune activity from the gut and, generally, promote DC 
homing potential toward the skin. Further detailed analy-
sis of the underlying and multiple mechanisms control-
ling the DC/lymphocyte circuitry will lead to more effi-
cient methods of controlling immune activity; if localized 
tissue-specific, immune manipulation can be achieved it 
should remove the need for blanket immunosuppressive 
therapies and facilitate the development of tissue-specific 
control of immunity in IBD. When we can upgrade our 
cell-based postal/zip code system from general area codes 
to satnav precision, individualized tissue-specific treat-
ments should become achievable. 
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